Cancer has often been explained through mutations in deoxyribonucleic acid (DNA) or changes in ribonucleic acid (RNA), but ...

What if a new combination of cancer drugs could sound an alarm, alerting the body's immune system to invoke a targeted ...

Targeting the WNT signaling pathway represents a promising strategy for cancer therapy. The field has evolved to include numerous inhibitors currently under preclinical and clinical investigation.

A research team at Kanazawa University, led by Professor Atsushi Mizokami, Associate Professor Koji Izumi and Specially ...

A new research paper was published in Volume 17 of Oncotarget on June 3, 2026, titled "The anticancer effects of PCAIs in ...

A previous trial involving patients with metastatic prostate cancer that was resistant to androgen pathway modulation (formerly referred to as castration-resistant) showed that adding talazoparib ...

Two KRAS-targeted strategies are starting to reshape treatment for metastatic pancreatic cancer after decades of limited progress with chemotherapy.

RASolute 302 findings herald a new standard of care in previously treated patients ...

There are around 46,000 new cases of prostate cancer each year in England and Wales, with 13% of these cases showing signs of ...